Original news and analysis on international IP policy
Pharmaceutical company Gilead Sciences has been noted first for developing a treatment for hepatitis C, which afflicts tens of millions around the world, and then for pricing it at jaw-dropping prices ($1000 per pill) in the United States and elsewhere. Now a group of health advocates has challenged Gilead's patent applications in five emerging economies.
Senators Blumenthal, Brown, Baldwin, and Udall introduced today a trade negotiation transparency bill that would require that all formal U.S. proposals for trade agreement restrictions on domestic regulations be posted on a website. This is a common sense policy that should be broadly supported. The bill would require policies similar to the transparency policies currently followed by the European Union and by intergovernmental organizations that set similar minimum regulatory standards. But it would be a major change in the current process for trade negotiations followed by the U.S. Trade Representative, which are infamously secretive, write Sean Flynn and David Levine.
An assessment of the World Health Organization Global Vaccine Action Plan aimed at delivering vaccination to all and boosting research into new vaccines found implementation to be “far off-track” in some areas. Today at the World Health Assembly, Libya put forward a new proposal at the Assembly to reduce vaccine prices and increase availability in developing countries.
“The Ebola outbreak shook this organization to its core,” World Health Organization Director General Margaret Chan said in opening the WHO’s annual assembly today. And the need to better construct the world’s emergency response systems has the biggest economies on the podium, with German Chancellor Angela Merkel speaking as chair of the Group of 7.
The World Health Organization is working to learn from the fast response on research and development for Ebola that led to effective treatments in a short time. It hopes that this changes the way R&D for emergency vaccines is done forever.
WARSAW -- More than twenty years after Poland’s parliament passed the Authors’ and Related Rights law of 1994, the Polish government is drafting three bills to modify the country’s intellectual property legislation. The first of the drafts prepared by the Polish Ministry of Culture and National heritage was submitted to the Parliament in March, and is currently being deliberated, while the ministry is finishing work on the remaining two drafts.
The World Health Organization today published its updated Model List of Essential Medicines, including high-priced new treatments for hepatitis C, cancers and multi-drug resistant tuberculosis (MDR-TB) that were quickly applauded by the public health advocacy community.
EU Trade Commissioner Cecilia Malmström published a concept paper on investor-state dispute settlement (ISDS) mechanisms to be included in the Trans-Atlantic Trade and Investment Partnership (TTIP).
From 8-22 May, US online search giant Google will open a streamlined portal for patent owners to let Google know about patents they are willing to sell at a price they set.
Least developed countries (LDCs) at the World Trade Organization have requested that a waiver allowing them to not enforce intellectual property rights on pharmaceutical products be extended beyond its deadline of 1 January 2016. The brand pharmaceutical industry this week stated that it supports access to medicines for LDCs but does not see the need for this extension as LDCs already benefit from a WTO waiver on all products until 2021.
the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) provided its recommendations on how to slow down antimicrobial resistance and boost antibiotic research and development. In addition, the association organised a forum on the subject today.
In Chile, pharmaceutical patents are almost exclusively the domain of foreign companies. Only a subset of drugs is protected by patents, while a much larger number of products is protected by trademarks, a study finds, offering for the first time empirical evidence on the use of primary and secondary patents in Chile.